公开(公告)号：US20210107988A1

公开(公告)日：2021-04-15

申请号：US16963701

申请日：2019-01-24

Applicant: GENMAB B.V.

Inventor： Simone OOSTINDIE ,  Andreas HOLLENSTEIN ,  Frank BEURSKENS ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Rob DE JONG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.

公开(公告)号：US20190276549A1

公开(公告)日：2019-09-12

申请号：US16345044

申请日：2017-11-01

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Marije OVERDIJK ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61P31/04 ,  A61P31/12 ,  A61P31/10

Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.

公开(公告)号：US20190144554A1

公开(公告)日：2019-05-16

申请号：US15780268

申请日：2016-12-01

Applicant: GENMAB B.V.

Inventor： Marije OVERDIJK ,  Kristin STRUMANE ,  Rik RADEMAKER ,  Esther BREIJ ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/62 ,  C07K16/30 ,  A61P35/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20250145720A1

公开(公告)日：2025-05-08

申请号：US18744540

申请日：2024-06-14

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Sandra VERPLOEGEN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  C07K16/00 ,  C07K16/36 ,  C07K16/40 ,  C07K19/00

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

公开(公告)号：US20210230301A1

公开(公告)日：2021-07-29

申请号：US17012102

申请日：2020-09-04

Applicant: GENMAB B.V.

Inventor： Rob N. DE JONG ,  Frank BEURSKENS ,  Paul PARREN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN ,  Arjen VLUG ,  Sandra VERPLOEGEN

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20150353636A1

公开(公告)日：2015-12-10

申请号：US14760135

申请日：2013-01-10

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Sandra VERPLOEGEN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  C07K16/40 ,  C07K19/00 ,  A61K51/10 ,  A61K39/395 ,  A61K47/48

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2319/30

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

Abstract translation: 本文描述的是包含变体Fc结构域的多肽和相关抗体。 当多肽，抗体或抗体与细胞表面上的靶标，抗原或抗原结合时，变体Fc结构域提供稳定的Fc：Fc相互作用，从而提供改善的补体依赖性细胞毒性（CDC）。